This page contains brief information about axicabtagene ciloleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Axicabtagene ciloleucel is approved to treat:
- B-cell non-Hodgkin lymphoma (NHL), including the following types:
- Diffuse large B-cell lymphoma (DLBCL).
- DLBCL in patients who had follicular lymphoma.
- Primary mediastinal large B-cell lymphoma.
- High-grade B-cell lymphoma.
It is used in adults whose disease has relapsed or has not gotten better after at least two other types of systemic treatment.
Axicabtagene ciloleucel is only available as part of a special program called Yescarta REMS (Risk Evaluation and Mitigation Strategies).
Axicabtagene ciloleucel is also being studied in the treatment of other types of cancer.
More About Axicabtagene Ciloleucel
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Axicabtagene Ciloleucel – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
